ipharmacenter Consulting services

Bimzelx (bimekizumab) showed marked superiority over Skyrizi (risankizumab) in improving symptoms of active psoriatic arthritis, achieving statistically significant results at Week 16 as measured by the ACR50 response. This marks the first time a licensed biologic therapy has shown clear superiority over an IL-23 inhibitor in psoriatic arthritis. BE BOLD represents the fourth head-to-head study within the Bimzelx clinical program to demonstrate superior outcomes in psoriatic

Eli Lilly and Company has released a public advisory highlighting possible safety issues with compounded formulations that combine tirzepatide and vitamin B12.   Also read: Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis The testing revealed a chemical impurity generated by the interaction between vitamin B12 and compounded tirzepatide, and Lilly notes that there is no information on how this impurity behaves in humans over the short or long term.